Compare Citius Pharmaceuticals Inc (CTXR) vs Nuscale Power Corporation (SMR) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Citius Pharmaceuticals Inc vs Nuscale Power Corporation — how do they compare? Citius Pharmaceuticals Inc trades at $0.77 (market cap $20.01M), while Nuscale Power Corporation trades at $9.64 (market cap $4.06B). The key difference: Nuscale Power Corporation is far larger — about 202.9× Citius Pharmaceuticals Inc's market cap, and Citius Pharmaceuticals Inc is trading nearer its 52-week high, Nuscale Power Corporation nearer its low. Which is the better fit depends on your goals.
| CTXR | SMR | |
|---|---|---|
Market Cap | $20.01M | $4.06B |
Sector | Health | Utilities |
52-Week High | $1.82 | $53.43 |
52-Week Low | $0.48 | $7.59 |
Enterprise Value | $16.23M | $2.99B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CTXR trades at $0.7554, up 11.58% today, with a bullish technical signal from moving averages. The company reported a net loss of $37.43M for 2025, with a negative net income margin of -823.34%, but shows revenue growth from its LYMPHIR launch. Recent news highlights commercial expansion and positive clinical data presentations at ASCO 2026.
The outlook is speculative; analyst consensus is strongly bullish (83.3% Buy), but high cash burn and consistent earnings misses pose significant risks. Investment potential hinges on successful commercialization of LYMPHIR to achieve profitability.
NuScale Power (SMR) trades at $9.58, up 4.36% today, with a bullish technical signal from moving averages but mixed oscillators. The company reported a net loss of $355.79 million on $31.48 million revenue in 2025, with a negative net margin of -3,888.7%. Recent news highlights regulatory progress for its small modular reactors and potential from AI data center power demand, though revenue plunged 98.8% year-over-year in Q2 2026.
Outlook hinges on commercial deployment success, with a consensus price target of $10.50 offering 9.6% upside. High execution risk and cash burn are key concerns, but analyst sentiment is 50% buy-rated. Investors face volatility from project timelines versus speculative growth potential in nuclear energy.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Citius Pharmaceuticals Inc
Citius Pharmaceuticals is a late-stage biopharmaceutical company focused on critical care products. Its pipeline includes anti-infectives and targeted immune therapies for conditions like cutaneous T-cell lymphoma.
Read more on CTXR →About Nuscale Power Corporation
NuScale Power Corporation is a leading developer of Small Modular Reactor (SMR) technology. The company's flagship product is a light water reactor SMR designed to generate clean, reliable, and scalable nuclear power. NuScale's technology is poised to address the global demand for carbon-free energy by offering a safer, smaller, and more flexible alternative to traditional large-scale nuclear power plants, with applications in electricity generation, desalination, and process heat.
Read more on SMR →
